Primo Shines at the 2025 Annual Conference of TSNM, showcasing Breakthrough Innovations

Primo has long been dedicated to advancing the field of nuclear medicine, constantly pushing the boundaries of innovation and quality. This year, we are proud to take the stage at the 2025 Annual Conference of Society of Nuclear Medicine, where our latest research has been officially recognized and featured—marking another milestone in our journey of excellence.

At 2025 conference, Primo will present several groundbreaking achievements:

The first successful automated synthesis of Tb-161 RLT in Taiwan, demonstrating Primo’s pioneering leadership in technological integration and clinical application.
A state-of-the-art pharmaceutical facility compliant with GMP standards, showcasing superior quality assurance and high-efficiency production capabilities.
Extensive experience in radiopharmaceutical R&D and clinical translation, bridging the gap between laboratory innovation and real-world medical practice.
Looking ahead, Primo will continue to advance nuclear medicine manufacturing with a focus on innovation, intelligent automation, and precision. Our mission is to build a radiopharmaceutical production system that meets the most rigorous international standards—driving the development of Radioligand Theranostics (RLT) toward a more accurate and personalized medical future.

At present, we have established a comprehensive nuclear medicine radiopharmaceutical service — from preclinical and clinical studies to drug development, automated synthesis, and APAC distribution!

We sincerely invite you to visit our booth to explore the future of nuclear medicine together and join us in shaping a new era of precision healthcare.

📅 Event Information
▸ Date: November 1, 2025 (Saturday) 8:20 ~ 16:30
▸ Venue: Chih-Teh Building, Taipei Veterans General Hospital
▸ Address: No. 201, Sec. 2, Shipai Rd., Beitou Dist., Taipei City 112, Taiwan
▸ Booth No.: 8

🎉 We warmly welcome you to visit our booth and exchange insights on the latest advances in radiopharmaceutical research and development!